Understanding a Positive Hepatitis B Core Antibody (Anti-HBc) Test Result
A positive hepatitis B core antibody (anti-HBc) test indicates previous exposure to the hepatitis B virus (HBV), which could represent either a past infection that has resolved, an ongoing chronic infection, or rarely, an acute infection in the "window period." 1 The interpretation depends on the results of other HBV serologic markers.
Interpretation of Positive Anti-HBc Based on Other Serologic Markers
Scenario 1: Anti-HBc Positive + HBsAg Negative + Anti-HBs Positive
- Interpretation: Resolved past HBV infection with immunity 1
- This is the most common scenario for a positive anti-HBc result
- The person has recovered from a previous HBV infection and developed natural immunity
- No further testing is required 1
Scenario 2: Anti-HBc Positive + HBsAg Positive + IgM Anti-HBc Positive
- Interpretation: Acute HBV infection 1
- High infectivity and risk of transmission
- Requires medical monitoring and possibly treatment
Scenario 3: Anti-HBc Positive + HBsAg Positive + IgM Anti-HBc Negative
- Interpretation: Chronic HBV infection 1
- Person is infectious and at risk for long-term complications
- Requires medical evaluation and possible treatment
Scenario 4: Anti-HBc Positive + HBsAg Negative + Anti-HBs Negative
- Interpretation: Four possibilities 1:
- Resolved infection with waning anti-HBs levels (most common)
- False-positive anti-HBc test result
- "Low-level" chronic HBV infection (occult HBV)
- Window period of acute infection (between disappearance of HBsAg and appearance of anti-HBs)
Clinical Significance and Management
For Isolated Anti-HBc (Scenario 4)
- HBV DNA testing may help determine if occult infection is present 1
- Hepatitis B vaccination can help distinguish between possibilities:
For Healthcare Settings
- Patients with positive anti-HBc who are also anti-HBs positive (>10 IU/mL) are considered immune from prior infection 1
- In dialysis settings, these patients require no further testing 1
- For transplantation, positive anti-HBc donors require special consideration due to risk of viral reactivation in immunosuppressed recipients 1
For Cancer Patients
- Patients who are HBcAb positive are at risk for HBV reactivation during immunosuppressive therapy, particularly with anti-CD20/CD52 monoclonal antibodies 1
- Prophylactic antiviral therapy may be indicated before starting immunosuppressive treatment
Common Pitfalls to Avoid
- Misinterpreting isolated anti-HBc: Don't assume chronic infection without additional testing
- Missing the window period: During acute infection resolution, HBsAg may disappear before anti-HBs appears, with anti-HBc being the only marker 1
- Overlooking reactivation risk: Patients with resolved HBV infection (anti-HBc positive) can experience reactivation during immunosuppression 1
- Incomplete testing: Testing only for HBsAg and anti-HBc without anti-HBs may miss important information about immunity status 1
Remember that the complete serologic profile (HBsAg, anti-HBc, and anti-HBs) provides the most accurate assessment of HBV status and should guide appropriate management decisions.